The acute promyelocytic leukemia (APL) t(15; 17) translocation generates a myl/retinoic acid receptor-(RAR-) chimeric gene that is transcribed as a fusion myl/RAR-amessenger RNA. Using primer sets derived from RAR-cr and my1 cDNAs, we were able to amplify the breakpoint sites of the fusion transcripts of all 35 APL RNA samples by reverse polymerase chain reaction (PCR) and nested primer approach of two rounds of amplification. DNA fragments of different size were obtained according to the chromosome 15 breakpoints (intron 3-bcr 3; exon &bcr 2; and intron 6-bcr 1). bcr 1 and bcr 3 represent the regions of the my1 locus most frequently involved among APL (48.5 and 34.2 of cases, HE MOLECULAR definition of chromosomal translo-T cation associated with hematopoietic tumors has provided important tools, either at the DNA or RNA level, for the diagnosis and the monitoring of patient response to therapy. Examples are the rearrangements of the bcr and c-ab1 genes in the t(9;22) of chronic myeloid leukemia,' the c-myc and Ig genes in the t(8;14) of Burkitt's lymphoma? and the bcl-2 in the t( 14;18) of follicular lymphomas?
M o m (Milano), Italy.
The publication costs of this artick were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. RAR-a/myl genes are expressed as fusion messenger RNAs (mRNAs) .5J [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] We have cloned and characterized the cDNA of the myl/RAR-a and my1 geneslo In this study, we designed a strategy for amplifying the fusion myl/RAR-a gene by polymerase chain reaction (PCR) for either the diagnosis or monitoring of the APL clone. Primers have been identified that allow the detection of the chimeric myl/RAR-a mRNA in 35 APL patients analyzed by reverse PCR and nested primer approach of two rounds of amplification. Based on this data, we used PCR to monitor minimal residual cells containing the t(15;17) transcript in five APL patients during the course of treatment.
MATERIALS AND METHODS
Bone marrow (BM) or peripheral blood (PB) samples were obtained from 35 APL patients after informed consent. The patients ranged in age from 4 to 70 years. The diagnosis of APL was made according to the French-AmericanBritish classification (FAB) criteria by using May-GriinwaldGiemsa staining. Twenty-seven cases displayed the typical morphology of the FAB-M3 subtype, ie, hypergranular marrow cells with bilobed nuclei and prominent Auer rods. Light microscopy evaluation of marrow cells in the remaining eight patients showed promyelocytes with bilobed andlor deeply indented nuclei with agranular or hypogranular cytoplasm and were classified as M3V according to FAB classification. Mononuclear cells were isolated by Ficoll-Hypaque centrifugation. At this stage, the preparations, containing greater than 90% of promyelocytes, were used for RNA and PCR analyses. Chromosome preparations were obtained from 24-hour unstimulated BM cell cultures, stained with quinacrine mustard (QFQ-banding technique), and 40 metaphases were routinely analyzed. Chromosome preparations of BM cells were adequate for the analysis in 28 of 35 cases (80%). Twenty-six cases manifested the specific translocation between chromosome 15 and 17, t(15;17)(q22,q21). Two patients displayed an apparently normal karyotype.
In vitro reverse transcription of 1 p, g of APL total RNA to cDNA was performed in a 20 pL volume for 15 minutes at 42°C containing 2.5 U of cloned Moloney murine leukemia virus (Mo-MLV) reverse transcriptase and random examers as primers, using a commercial kit (GeneAmp RNA PCR Kit; Perkin Elmer-Cetus, Norwalk, CT) according to the manufacturer's conditions. A volume of 5 pL was then 3' primers. After an initial denaturation at 95°C for 5 minutes, denaturation, annealing, and extension were performed on an automated heat block (DNA Thermal Cycler; Perkin Elmer-Cetus) at 95°C for 1 minute, S O T for 1 minute, and 72°C for 1 minute. respectively, for a total of 30 cycles. At the end, 5 pL of first PCR product was used for a second round of amplification for further 30 cycles using a nested primer (RX). Finally, 10 pL of PCR mixture was run on a 3% Nusieve agarose gel stained with ethidium bromide and visualized under a U V lamp. As a negative control.
RNA isolated from GF-DX, a human granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent myeloid cell line A -w 8 8 [I( 1S;17) negative] recently established in our laboratory, was used (A. Rambaldi et al, manuscript submitted). Amplification of the @-actin mRNA was accomplished with 5 pL of the same cDNA preparation used to identify myl/RAR-a junctions. The following primer sequences were used: forward 5' CCITCCT'GGGCATG-GAGTCCTG-3' and reverse 5' GGAGCAATGATCITGATCITC 3'. In selected experiments. 10 pL of the PCR products fractionated by electrophoresis through a I .% agarose gel was transferred to nylon membranes (Genescreen Plus; New England Nuclear, Boston, MA). Prehybridization, hybridization, and washings were performed according to manufacturer's instructions. as previously reported." The following primer was used to hybridize the PCR blots: S'-GAGTCTGAGGAGGGGAAGGA-3'. according to established procedures.IJ
RESULTS

PCR amplification of the myllRAR-afision gene in APL.
We have previously rcported that the RAR-a breakpoint of APL occurs consistently within an approximatcly 16-kb DNA fragment of the RAR-a intron 2.X.u Further studies on mapping of chromosome 15 breakpoints have indicated that at lcast ihrce regions of thc my1 locus are involvcd in thc translocation breakpoints (intron 3-bcr 3; exon 6-bcr 2; and intron 6-bcr l).ls According to the nucleotide sequence of a myl1RAR-a cDNA,'" a set of amplimcrs was selected. Figurc 1 shows the positions of M2, M4, R5, and R8 rclative to the sequence of myl1RAR-a derived from our previous report."' Primer M4, derived from my1 exon 3, and primer R5 were used as a first cycle of PCR; then a second round of amplification was performed by using R8 as a nested primer. Figure 2A shows the results of PCR amplification of thrcc diffcrcnt APL cases, representative of bcr 1, bcr 2, and bcr 3. Nucleotide scquence analysis of the different myl/RAR-a junctions generated by PCR amplification has shown that the additional heterogcneity observed is due to alternative splicing of the my1 portion.Is To obtain a better resolution of the myl/RAR-a junctions corresponding to bcr 1 and bcr 2, a primer derived from a more 3' my1 sequence (M2 from my1 exon 5) was used for PCR amplification. As shown in Fig 2B, was not available for molecular analysis, but a positive PCR result was still apparent even after the patient received a reinduction cycle with idarubicin. Patient no. 1 underwent allogeneic BM transplantation (BMT) and the BM aspirate performed 8 months after BMT did not show the presence of MRD. Similarly, in patient no. 4, as shown in Fig 4, no cells carrying the t(15;17) transcripts could be detected in a remission sample 21 months after autologous BMT. Despite being in clinical remission, as confirmed by the absence of any metaphases carrying the t(15;17), the fusion transcript myl/RAR-u could be detected in BM of patient no. 5 after 7 months of ATRA treatment. Similar findings on the persistence of myl/RAR-a fusion gene as assessed by PCR amplification were obtained in three additional patiebts during the time they received ATRA alone (data not shown). Table 3 summarizes the findings on MRD in APL patients obtained either by PCR amplification of the myl/RAR-a junctions or by standard cytogenetics. With the exception of patient no. 3 (BM sample 6 months after diagnosis), in none of the cases positive for minimal residual cells by PCR could the t(15;17) be detected. To determine the sensitivity of PCR amplification in our study, RNA from patient no. 3 was serially diluted by mixing with GF-D8 RNA, reverse transcribed and amplified as described in Materials and Methods. As shown in Fig 5, the PCR can detect the presence Of myl/RAR-a fusion gene in the presence of less than 0.1 ng total RNA, which represents a final dilution between lo-' and lO-5. 3A and B, the PCR products obtained either from the first cycle and after the nested amplification were blotted and then hybridized with an internal oligonucleotide (see Materials and Methods). Amplification of the p-actin gene was used to eliminate the possibility of false-negative results. Cells from all marrow-derived samples equally expressed this gene after one cycle of amplification (Fig 3) . As shown, DNA fragments of 326 bp corresponding to the ones present at diagnosis were detectable after PCR analysis in patients no. 1 and 3 during the time of clinical remission (3 months and 6 to 8 months, respectively) . Interestingly, one of the two patients (no. 3) relapsed 3 months after the first PCR sample tested. Unfortunately, the BM of the relapse
DISCUSSION
The detection of MRD in patients undergoing treatment for hematologic malignancies has become an important goal, not only to monitor the effectiveness of therapy but also to detect an impending relapse." The application of techniques based on the enzymatic amplification of DNA target sequences by PCR has attracted much attention due to the extreme sensitivity and specificity of the technique.'* If the two primers flank a translocation junction, exponential amplification is dependent on the presence of tumor cells carrying the translocation, thus providing a very sensitive method for tumor dete~ti0n.I~ Tible 3. MRD In APL P a n t s Thc prcscncc of thc chimcric myl/RAR-a fusion gcnc, as a conscqucncc of thc rcciprocal translocation bctwccn thc my1 and RAR-a loci, has suggcstcd thc possibility of cxtcnding to APL, a similar approach that has bccn cxtcnsivcly uscd for chronic mycloid Icukcmia.g' Thc diffcrent rcgions of thc my1 locus involvcd in thc 15 transltmtion brcakpoints and thc prcscncc o f altcrnativc splicing of thc my1 portion arc rcsponsiblc for the grcat hctcrogcncity of myl/RAR-a junctions obscrvcd among APL paticnts.I5 Morcovcr, thc altcrnativc usc o f two RAR-a polyadcnylation sitcs gcncratcs myl/RAR-a transcripts of dificrcnt sizcs.ll.iz Thc sct o f amplimcrs applicd in thc prcscnt study allowcd for thc amplification of myl/RAR-a junctions in 35 APL paticnts, thc largcst casclist of APL paticnts studicd so far by PCR amplification. Thc paticnts includcd wcrc rcprcscntativc of diffcrcnt agc, of M3 and M3v FAB subtypc, and of diffcrcnt chromosomc 15 brcakpoints. Thc rcsolution of thc fragmcnts obtaincd by thc two rounds of amplification and thc possibility of visualizing thcm by standard cthidium staining (as shown in Figs 2 and 4) madc thc approach outlincd hcrcin thc casicst and most rapid mcthod for idcntifying the t(15;17), even in thc cases in which convcntional cytogcnctics failed. As an altcrnativc approach for thc molccular idcntification of thc t( 15;17) brcakpoint sitc of APL. wc considcrcd the amplification of thc RAR-a/myl fusion transcript. The observation that thc RAR-a/myl transcript was prcscnt in most, but not all, APL caws sccmcd to favor thc usc of myl/RAR-a as the targct gcnc for PCR amplification of thc APL clone.?' Thc dctcction of MRD in APL will bc important in cvaluating an impcnding rclapsc and thc cffccts o f diffcrcnt thcrapcutic approachcs. As shown by thc prcscntcd data, PCR analysis was shown to bc superior in dctecting rcsidual APL cclls as comparcd with morphology and standard cytogcnctics. In fact, thc rclapsc of patient no. 3 was hcraldcd by PCR 3 months bcforc thc clinical appearancc o f Icukcmia. By thc samc approach, wc could show that high doscs of chcmothcrapy and total body irradiation associatcd with cithcr autologous or allogcncic BMT rcprcscnt an cffcctivc and potcntially cradicating thcrapcutic stratcgy of APL. On thc contrary, trcatmcnt with ATRA alonc, dcspitc rcsulting in complctc hcmatologic remission as asscsscd by morphology, cytogcnctics, and molccular analysis by Southcrn blot tcchniquc,l6 did not rcsult in complctc cradication of thc APL clonc. Thc rcccnt findings that thc rcmission induccd by ATRA docs not appcar to bc long tcrm sccm to support our molccular results.??
